Cargando…

Diazoxide protects against doxorubicin-induced cardiotoxicity in the rat

AIM: Chemotherapy with doxorubicin is limited by cardiotoxicity. Free radical generation and mitochondrial dysfunction are thought to contribute to doxorubicin-induced cardiac failure. In this study we wanted to investigate if opening of mitochondrial K(ATP)-channels by diazoxide is protective again...

Descripción completa

Detalles Bibliográficos
Autores principales: Hole, Lisa Drange, Larsen, Terje Hjalmar, Fossan, Kjell Ove, Limé, Fredrik, Schjøtt, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4045949/
https://www.ncbi.nlm.nih.gov/pubmed/24887454
http://dx.doi.org/10.1186/2050-6511-15-28
_version_ 1782319417693044736
author Hole, Lisa Drange
Larsen, Terje Hjalmar
Fossan, Kjell Ove
Limé, Fredrik
Schjøtt, Jan
author_facet Hole, Lisa Drange
Larsen, Terje Hjalmar
Fossan, Kjell Ove
Limé, Fredrik
Schjøtt, Jan
author_sort Hole, Lisa Drange
collection PubMed
description AIM: Chemotherapy with doxorubicin is limited by cardiotoxicity. Free radical generation and mitochondrial dysfunction are thought to contribute to doxorubicin-induced cardiac failure. In this study we wanted to investigate if opening of mitochondrial K(ATP)-channels by diazoxide is protective against doxorubicin cardiotoxicity, and if 5-hydroxydecanoate (5-HD), a selective mitochondrial K(ATP)-channel antagonist, abolished any protection by this intervention. METHODS: Wistar rats were divided into 7 groups (n = 6) and followed for 10 days with 5 intervention groups including the following treatments: (1) Diazoxide and doxorubicin, (2) diazoxide and 5-hydroxydecanoate (5-HD), (3) 5-HD and doxorubicin, (4) diazoxide and saline and (5) 5-HD and saline. On day 1, 3, 5 and 7 the animals received intraperitoneal (i.p.) injections with 10 mg/kg diazoxide and/or 40 mg/kg 5-HD, 30 minutes before i.p. injections with 3.0 mg/kg doxorubicin. One control group received only saline injections and the other control group received saline 30 minutes prior to 3.0 mg/kg doxorubicin. On day 10 the hearts were excised and Langendorff-perfused. Cardiac function was assessed by an intraventricular balloon and biochemical effects by release of hydrogen peroxide (H(2)O(2)) and troponin-T (TnT) in effluate from the isolated hearts, and by myocardial content of doxorubicin. RESULTS: Doxorubicin treatment produced a significant loss in left ventricular developed pressure (LVDP) (p < 0.05) and an increase in both H(2)O(2) and TnT release in effluate (p < 0.05). Diazoxide significantly attenuated the decrease in LVDP (p < 0.05) and abolished the increased release of H(2)O(2) and TnT (p < 0.05). 5-HD abolished the effects of pretreatment with diazoxide, and these effects were not associated with reduced myocardial accumulation of doxorubicin. CONCLUSIONS: Pretreatment with diazoxide attenuates doxorubicin-induced cardiac dysfunction in the rat, measured by physiological indices and TnT and H(2)O(2) in effluate from isolated hearts. The effect could be mediated by opening of mitochondrial K(ATP)-channels, reduced doxorubicin-associated free radical generation and decreased cardiomyocyte damage. Diazoxide represents a promising protective intervention against doxorubicin-induced acute cardiotoxicity.
format Online
Article
Text
id pubmed-4045949
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40459492014-06-06 Diazoxide protects against doxorubicin-induced cardiotoxicity in the rat Hole, Lisa Drange Larsen, Terje Hjalmar Fossan, Kjell Ove Limé, Fredrik Schjøtt, Jan BMC Pharmacol Toxicol Research Article AIM: Chemotherapy with doxorubicin is limited by cardiotoxicity. Free radical generation and mitochondrial dysfunction are thought to contribute to doxorubicin-induced cardiac failure. In this study we wanted to investigate if opening of mitochondrial K(ATP)-channels by diazoxide is protective against doxorubicin cardiotoxicity, and if 5-hydroxydecanoate (5-HD), a selective mitochondrial K(ATP)-channel antagonist, abolished any protection by this intervention. METHODS: Wistar rats were divided into 7 groups (n = 6) and followed for 10 days with 5 intervention groups including the following treatments: (1) Diazoxide and doxorubicin, (2) diazoxide and 5-hydroxydecanoate (5-HD), (3) 5-HD and doxorubicin, (4) diazoxide and saline and (5) 5-HD and saline. On day 1, 3, 5 and 7 the animals received intraperitoneal (i.p.) injections with 10 mg/kg diazoxide and/or 40 mg/kg 5-HD, 30 minutes before i.p. injections with 3.0 mg/kg doxorubicin. One control group received only saline injections and the other control group received saline 30 minutes prior to 3.0 mg/kg doxorubicin. On day 10 the hearts were excised and Langendorff-perfused. Cardiac function was assessed by an intraventricular balloon and biochemical effects by release of hydrogen peroxide (H(2)O(2)) and troponin-T (TnT) in effluate from the isolated hearts, and by myocardial content of doxorubicin. RESULTS: Doxorubicin treatment produced a significant loss in left ventricular developed pressure (LVDP) (p < 0.05) and an increase in both H(2)O(2) and TnT release in effluate (p < 0.05). Diazoxide significantly attenuated the decrease in LVDP (p < 0.05) and abolished the increased release of H(2)O(2) and TnT (p < 0.05). 5-HD abolished the effects of pretreatment with diazoxide, and these effects were not associated with reduced myocardial accumulation of doxorubicin. CONCLUSIONS: Pretreatment with diazoxide attenuates doxorubicin-induced cardiac dysfunction in the rat, measured by physiological indices and TnT and H(2)O(2) in effluate from isolated hearts. The effect could be mediated by opening of mitochondrial K(ATP)-channels, reduced doxorubicin-associated free radical generation and decreased cardiomyocyte damage. Diazoxide represents a promising protective intervention against doxorubicin-induced acute cardiotoxicity. BioMed Central 2014-05-27 /pmc/articles/PMC4045949/ /pubmed/24887454 http://dx.doi.org/10.1186/2050-6511-15-28 Text en Copyright © 2014 Hole et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Hole, Lisa Drange
Larsen, Terje Hjalmar
Fossan, Kjell Ove
Limé, Fredrik
Schjøtt, Jan
Diazoxide protects against doxorubicin-induced cardiotoxicity in the rat
title Diazoxide protects against doxorubicin-induced cardiotoxicity in the rat
title_full Diazoxide protects against doxorubicin-induced cardiotoxicity in the rat
title_fullStr Diazoxide protects against doxorubicin-induced cardiotoxicity in the rat
title_full_unstemmed Diazoxide protects against doxorubicin-induced cardiotoxicity in the rat
title_short Diazoxide protects against doxorubicin-induced cardiotoxicity in the rat
title_sort diazoxide protects against doxorubicin-induced cardiotoxicity in the rat
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4045949/
https://www.ncbi.nlm.nih.gov/pubmed/24887454
http://dx.doi.org/10.1186/2050-6511-15-28
work_keys_str_mv AT holelisadrange diazoxideprotectsagainstdoxorubicininducedcardiotoxicityintherat
AT larsenterjehjalmar diazoxideprotectsagainstdoxorubicininducedcardiotoxicityintherat
AT fossankjellove diazoxideprotectsagainstdoxorubicininducedcardiotoxicityintherat
AT limefredrik diazoxideprotectsagainstdoxorubicininducedcardiotoxicityintherat
AT schjøttjan diazoxideprotectsagainstdoxorubicininducedcardiotoxicityintherat